Bank of America Warns of 10%+ Drop in Q3 Investment Banking Fees

Bank of America Corporation (NYSE:BAC) expects third-quarter investment banking fees to fall by at least 10% year over year, which highlights a broader normalization across capital markets after an unusually strong first half of 2026. BofA expects investment banking fees of roughly $1.6 billion to $1.8 billion in the third quarter, compared with $2 billion a year earlier. CEO Brian Moynihan said the broader investment banking market is also down around 10%, suggesting that the softer quarter reflects a cooling in industry activity rather than a company-specific breakdown.

The comparison with the second quarter illustrates how sharp the normalization is. BofA’s investment banking fees had risen 50% year over year to $2.1 billion in Q2, while sales and trading revenue reached a record $7.1 billion. The current outlook therefore represents a pullback from elevated levels rather than a reversal of the broader recovery in dealmaking. Global M&A activity remained substantial in the first half of 2026, with more than $3 trillion of announced transactions, providing evidence that corporate deal appetite has remained relatively healthy even as quarterly activity fluctuates.

BofA’s Strong First Half Leaves Room for a Temporary Q3 Pullback

From a longer-term perspective, the normalization does not necessarily undermine Bank of America Corporation’s capital-markets franchise. Investment banking revenues remain well above the depressed levels seen during the earlier downturn in deal activity, while the bank continues to have a substantial pipeline of potential transactions. Moynihan’s comments that the pipeline remains strong suggest that some of the current weakness could reflect the timing of transactions rather than a fundamental loss of corporate demand for M&A, financing or advisory services.

BofA also has a diversified earnings base that makes it less dependent on any single capital-markets cycle. Its second-quarter net interest income increased 9% to $16 billion, while average loans and leases grew 8%. That provides a more stable source of revenue as investment banking normalizes. In this context, the Q3 decline can be viewed as a shift away from exceptionally strong capital-markets contributions rather than evidence that the bank’s broader earnings trajectory has deteriorated.

BofA Faces Pressure as Exceptional Investment Banking Growth Fades

The main risk is that normalization lasts longer than expected. Bank of America Corporation’s projected $1.6 billion to $1.8 billion in third-quarter investment banking fees would put revenue below both the $2 billion generated a year earlier and the $2.1 billion recorded in Q2. If deal activity continues to moderate, the exceptionally strong growth seen earlier in 2026 could become increasingly difficult to sustain, putting pressure on overall revenue growth and investor expectations.

The comparison with the broader market also matters. BofA expects its investment banking fees to decline broadly in line with the approximately 10% industry decline, but Moynihan indicated that the bank is less exposed to some of the areas that have been particularly active. That means a continued shift in the composition of capital-markets activity could limit BofA’s ability to capture the next phase of the recovery, even if overall M&A and financing volumes remain relatively healthy.

Conclusion

Bank of America Corporation’s Q3 outlook is best understood as a profile of capital-markets normalization after an exceptionally strong first half, rather than a standalone deterioration in the bank’s franchise. Investment banking fees are coming down from elevated levels, while trading revenue is expected to be flat, but a strong deal pipeline and diversified banking income provide important support. The key issue for investors is whether this is simply a temporary pause after a powerful capital-markets rebound or the beginning of a longer period of slower deal activity.

READ NEXT: BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough and From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure 

This article is originally published at Insider Monkey.